Claude tad smith8/4/2023 ![]() ![]() Brisbane is studying the potential for a novel imaging technology, micro-ultrasound, for detection and prognosis of prostate cancer. If successful, this study will be foundational in evaluating if micro-ultrasound is equivalent to MRI.The potential for integrating micro-ultrasound-based treatment monitoring into technologies like HIFU for prostate cancer will be investigated.A machine-learning algorithm will be developed to aid clinicians with diagnosing prostate cancer in real-time, possibly enabling micro-ultrasound use as a type of male mammogram.In this trial, patients scheduled for radical prostatectomy will obtain pre-operative micro-ultrasound and MRI evaluations. ![]() Brisbane will conduct a clinical trial to compare micro-ultrasound to MRI and to the final pathology following prostate removal. Wayne Brisbane is studying the potential for micro-ultrasound in prostate cancer imaging. Micro-ultrasound is a new imaging technology that has a 300% improvement in resolution compared to traditional ultrasound, and thus is highly promising for enabling visualization of prostate cancer.Micro-Ultrasound and MRI Investigation of Human Prostate Cancer This may result in an effective new therapeutic strategy to prevent or treat metastatic prostate cancerĢ020 Lowell Milken-PCF Young Investigator Award Arriaga is studying the biology of prostate cancer bone metastasis, specifically the role of ATAD2, and a driver of bone metastasis and possible new treatment target. If successful, this will project will determine how ATAD2 impacts the development of bone metastasis and resistance to hormonal therapies, and validate its potential as a novel therapeutic target in metastatic prostate cancer.In addition, the potential for ATAD2-targeting small molecule inhibitors as a new treatment for prostate cancer in combination with hormone therapy will be tested in preclinical models.Arriaga will determine the molecular basis by which ATAD2 contributes to prostate cancer bone metastasis. Juan Arriaga has discovered the protein ATAD2 as a major player in prostate cancer bone metastasis, using a unique mouse model of bone metastasis that is molecularly conserved with human prostate cancer. In order to develop novel and more effective therapies for metastatic prostate cancer, a better understanding of the biology of bone metastasis is needed. The most common site of prostate cancer metastasis is to bone, which is a major contributor to the morbidity and mortality of this disease.Investigating Novel Epigenetic Drivers of Bone Metastasis and Treatment Response in Metastatic Castration-Resistant Prostate Cancer Mentors: Cory Abate Shen, PhD Andreas Califano, PhD Mark Rubin, MD ![]() The PCF Young Investigator Award-Class of 2020 recipients are:Ģ020 Tad Smith & Caroline Fitzgibbons-PCF Young Investigator Award ![]() Home » Young Investigator Award – Class of 2020
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |